Intravacc, a Netherlands-based company that deals with translational research and development of preventive and therapeutic vaccines, announced on Wednesday that that it has received a contract from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG).
The deal includes base and options that are likely to total USD14.6m.
The company is developing a prophylactic vaccine based on its proprietary outer membrane vesicles (OMV) platform technology. The NG vaccine is called NGoXIM and is based on gonococcal OMVs integrated with sustained-release microspheres containing recombinant human IL-12, and will be dosed intranasally.
Intravacc is developing a complete production process for NGoXIM to generate vaccine batches under Good Manufacturing Practices.
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial